SCHEMBL843420

SCHEMBL843420

COC(=O)c1cncn1C1c2cc(F)ccc2NC(=O)C1(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.39
MAPK1 P28482 1/20 0.35
MAP2K4 P45985 1/20 0.34
SNRNP200 O75643 2/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 3/20 0.33
ALPL P05186 1/20 0.33
GRM2 Q14416 1/20 0.33
PARP1 P09874 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 2/20 0.32
CYP11B1 P15538 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL843144 0.92 CYP11B2 (0.40) CYP11B2MAPK1MAP2K4SNRNP200TP53
SCHEMBL863072 0.89 CYP11B2 (0.52) CYP11B2KMT2AMEN1CYP11B1
SCHEMBL842386 0.86 CYP11B2 (0.48) CYP11B2MAPK1ALDH1A1CYP11B1KDM4E
SCHEMBL842863 0.77 SNRNP200 (0.38) MAP2K4SNRNP200TP53POLBKMT2A
SCHEMBL8190171 0.75 CYP11B2 (0.36) CYP11B2KMT2A
SCHEMBL842870 0.75 CYP11B2 (0.63) CYP11B2POLBKMT2AALDH1A1MEN1
SCHEMBL2818227 0.73 CYP11B2 (0.58) CYP11B2MAPK1ALDH1A1CYP11B1KDM4E
SCHEMBL2818670 0.72 CYP11B2 (0.45) CYP11B2MAPK1ALDH1A1CYP11B1SMN1; SMN2
SCHEMBL843079 0.72 CYP11B2 (0.43) CYP11B2TP53
SCHEMBL2817696 0.71 CYP17A1 (0.40) CYP11B2KMT2AALDH1A1CYP11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143278-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
US-8143278-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
US-8143278-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
US-20100093711-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-15 US disclosed
US-20100093711-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-15 US disclosed
US-20100093711-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-15 US disclosed
EP-2121652-A1 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS Novartis AG (CH) 2009-11-25 EP disclosed
WO-2008076860-A1 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed
WO-2008076860-A1 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093711-A1 ORGANIC COMPOUNDS CYP11B1, HSD11B1, CYP11B2 CYP11B2 3/4885MAPK1 1399/4885MAP2K4 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.